









Markets
/
Stocks
/
nasdaq-nvno
/

enVVeno Medical Corp

NVNO

10.420USD

+1.070+11.44%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

6.02MMarket Cap

LossP/E TTM



enVVeno Medical Corp

10.420

+1.070+11.44%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of enVVeno Medical Corp

Currency: USD Updated: 2026-02-06

Key Insights

enVVeno Medical Corp's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 184 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 12.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

enVVeno Medical Corp's Score

Industry at a Glance

Industry Ranking

184 / 392

Overall Ranking

352 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

enVVeno Medical Corp Highlights

StrengthsRisks

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

Overvalued

The company’s latest PE is -0.28, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 169.95K shares, decreasing 28.78% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 834.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 8.32.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

12.500

Target Price

+1517.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of enVVeno Medical Corp is 5.44, ranking 366 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.44

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

enVVeno Medical Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of enVVeno Medical Corp is 6.35, ranking 291 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.28, which is -10.28% below the recent high of -0.25 and -3812.78% above the recent low of -10.81.

Score

Industry at a Glance

Previous score

6.35

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 184/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of enVVeno Medical Corp is 6.00, ranking 340 out of 392 in the Biotechnology & Medical Research industry. The average price target is 12.50, with a high of 12.50 and a low of 12.50.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

12.500

Target Price

+1517.29%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

enVVeno Medical Corp

NVNO

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of enVVeno Medical Corp is 7.20, ranking 92 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 12.92 and the support level at 8.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.74

Change

0.46

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.086

Sell

RSI(14)

45.647

Neutral

STOCH(KDJ)(9,3,3)

26.271

Neutral

ATR(14)

1.410

Low Volatility

CCI(14)

-73.144

Neutral

Williams %R

64.402

Sell

TRIX(12,20)

-0.723

Sell

StochRSI(14)

84.637

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

10.100

Buy

MA10

10.345

Buy

MA20

11.013

Sell

MA50

11.745

Sell

MA100

15.371

Sell

MA200

9.438

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of enVVeno Medical Corp is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 25.92%, representing a quarter-over-quarter decrease of 7.86%. The largest institutional shareholder is The Vanguard, holding a total of 8.55K shares, representing 1.30% of shares outstanding, with 61.94% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Satterfield (Thomas A Jr)

1.82M

Perceptive Advisors LLC

1.76M

+36.89%

Kingdon Capital Management, L.L.C.

1.36M

+58.19%

CM Management, LLC

600.00K

The Vanguard Group, Inc.

Star Investors

861.19K

+23.32%

Berman (Robert Andrew)

222.24K

+899.44%

Geode Capital Management, L.L.C.

201.24K

+0.87%

J.P. Morgan Securities LLC

182.32K

+0.01%

Susquehanna International Group, LLP

154.47K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of enVVeno Medical Corp is 1.44, ranking 316 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.13. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.